Benzinga | Aug 20, 2021 07:27AM EDT

Benchmark Initiates Coverage On Alterity Therapeutics with Speculative Buy Rating, Announces Price Target of $4

Benchmark analyst Aydin Huseynov initiates coverage on Alterity Therapeutics (NASDAQ:ATHE) with a Speculative Buy rating and announces Price Target of $4.